Crinetics Pharmaceuticals Inc. has announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating CRN09682 for the treatment of metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics' proprietary nonpeptide drug conjugate (NDC) platform, designed to target SST2-expressing tumor cells and deliver a cytotoxic payload directly within the tumor. The BRAVESST2 trial is a first-in-human, open-label, dose-escalation study with a planned dose expansion phase to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682. Up to 150 participants are expected to be enrolled. The results of the study have not yet been presented.